KLRA (Kailera Therapeutics) FCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics FCF Margin %?

Kailera Therapeutics KLRA +2.24% 11 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 952 Biotechnology companies, Kailera Therapeutics ranks worse than 105041.91% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kailera Therapeutics's Free Cash Flow for the six months ended in Dec. 2025 was $-122.30 Mil. Kailera Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Kailera Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Kailera Therapeutics's current FCF Yield % is -5.45%.

The historical rank and industry rank for Kailera Therapeutics's FCF Margin % or its related term are showing as below:


KLRA's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28
* Ranked among companies with meaningful FCF Margin % only.

Kailera Therapeutics FCF Margin % Related Terms

Kailera Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics FCF Margin % Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
FCF Margin %
0.00 0.00

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
FCF Margin % 0.00 0.00

KLRA vs VCEL, NUVB, IOVA: FCF Margin % Comparison

For the Biotechnology subindustry, Kailera Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kailera Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kailera Therapeutics's FCF Margin % falls into.


KLRA
11GF Score
Kailera Therapeutics Inc KLRA
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kailera Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-122.298/0
= %

Kailera Therapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-122.298/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Kailera Therapeutics (KLRA) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kailera Therapeutics and its competitors. According to the industry distribution chart, Kailera Therapeutics ranks #999999 out of 952 companies in the Biotechnology industry.
Is Kailera Therapeutics' FCF Margin % too high?
Kailera Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Kailera Therapeutics ranks #999999 out of 952 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' FCF Margin % compare to VCEL and NUVB?
According to the Biotechnology industry distribution chart, Kailera Therapeutics ranks #999999 out of 952 companies for FCF Margin %. This places Kailera Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price